Clinical trials: Asthma; Eosinophilic
Eosinophilic Asthma, Chronic Sinusitis
Eosinophils Endotypes in Chronic Airway Inflammatory Diseases
Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are frequently described as unified airway inflammatory diseases. Both heavily impacts quality of life with substantial productivity loss.
- Conditions
- Eosinophilic Asthma, Chronic Sinusitis, Eosinophilic Rhinitis
- Trial name
- PLEIAD (NCT04187976)
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Lille
Asthma, Eosinophilic Asthma
Effect of Mepolizumab on Severe Eosinophilic Asthma
Two parts: A:Case-control study including 15 healthy adult donors and 15 severe adult eosinophilic asthmatics selected for treatment with mepolizumab.
- Trial name
- EMESEA (NCT04641741)
- Testing
- Mepolizumab 100 MG
- Where
- 5 sites in Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospital Clinico Universitario de Santiago
Asthma
A Study to Test if TEV-53275 is Effective in Relieving Asthma
The primary objective of the study is to evaluate the efficacy of TEV-53275 administered subcutaneously (sc) in adult participants with persistent asthma and an eosinophilic phenotype compared to placebo.
- Trial name
- NCT04847674
- Testing
- TEV-53275 Dose A, TEV-53275 Dose B
- Where
- 82 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Obstructive Pulmonary Disease
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma.
- Trial name
- SPEED (NCT06862206)
- Testing
- benralizumab
- Where
- 36 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma, Bronchial
A Non-interventional, Prospective Study With Benralizumab
This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients…
- Trial name
- AIR POWER (NCT06422078)
- Where
- 41 sites in Germany
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Airway Auto Immunity in Asthma
IL-13 Blockade and Airway Autoimmunity in Asthma
It has been observed that certain section of patients having severe to moderate Asthma, do not benefit from oral corticosteroids and IL-5 blocking biologics.
- Trial name
- IL-SAA (NCT05564078)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- McMaster University
Asthma
Non-Eosinophilic Biological Effects of IL-5
This study aims to investigate the role of IL-5 in suppressing anti-viral immune responses in bronchial epithelial cells (BECs) and in peripheral blood mononuclear cells (PBMCs) from 5 people with asthma.
- Trial name
- NCT06026202
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Imperial College London
Allergic Bronchopulmonary Aspergillosis, ABPA
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma
- Trial name
- NCT07828327
- Testing
- Depemokimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
Asthma, Asthma, Bronchial
Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma.
This is an exploratory, randomized, subject- and investigator-blinded, placebo-controlled mode-of-action study to demonstrate the anti-inflammatory effects of fevipiprant compared to placebo after 12 weeks of treatment in 48…
- Conditions
- Asthma, Asthma, Bronchial, Bronchial Asthma, Eosinophilia
- Trial name
- NCT03989635
- Testing
- QAW039
- Sponsor
- Novartis Pharmaceuticals
Asthma With Eosinophilic Phenotype
A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype.
- Trial name
- NCT05522439
- Testing
- SHR-1703
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Eosinophilic Asthma
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines. 2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction. 3.
- Trial name
- NCT07250594
- Testing
- AD17002, Formulation buffer
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Severe Eosinophilic Asthma
A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
Severe eosinophilic asthma (SEA) is associated with poor disease control and compromised health-related quality of life (HRQoL), leading to a substantial psychosocial and economic disease burden.
- Trial name
- EMPOWAIR (NCT05440656)
- Testing
- Cohort
- Where
- 13 sites in Greece
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
- Trial name
- BREADTH (NCT07323654)
- Testing
- KT-621
- Where
- 81 sites in United States, Argentina and 11 more
- Volunteers
- 264 people
- Sponsor
- Kymera Therapeutics, Inc.
Asthma
Efficacy and Safety Study of 610 in Patients With Severe Asthma
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
- Trial name
- NCT06323213
- Testing
- 610
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Asthma
Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT)
An open-label, single-arm, non-interventional, prospective, multicenter study involving primary data collection within real-world settings for patients who receive benralizumab for treatment of severe uncontrolled eosinophilic…
- Trial name
- NCT05734339
- Where
- 6 sites in Taiwan
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of…
- Trial name
- BRISOTE (NCT06750289)
- Testing
- ICS-LABA, benralizumab
- Where
- 86 sites in United States, Bulgaria and 11 more
- Volunteers
- 130 people
- Sponsor
- AstraZeneca
Food Allergy, Asthma
Assessing Risk of Food Insecurity Within Households of Children With Food Allergy
Our central hypothesis is that dietary limitations introduced by food allergy will contribute to increased food insecurity in households with food allergic children when compared to food insecure households without food allergic…
- Conditions
- Food Allergy, Asthma, Allergic Rhinitis, Atopic Dermatitis
- Trial name
- NCT01897506
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Eosinophilic Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Eosinophil Subpopulations in Eosinophilic-associated Diseases
This single-center, non-commercial study will involve 160 participants (80 with eosinophilic asthma (EA), 30 with eosinophilic granulomatosis with polyangiitis (EGPA), 25 with hypereosinophilic syndrome (HES), and 25 healthy…
- Conditions
- Eosinophilic Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
- Trial name
- IREOS (NCT06911775)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Florence
Respiratory System Agents, Anti-Asthmatic Agents
Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Background: Eosinophils are white blood cells that help fight infections. High eosinophil levels can damage people s organs, causing hypereosinophilic syndrome (HES).
- Conditions
- Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders
- Trial name
- HESIL5R (NCT02130882)
- Testing
- benralizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Benralizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5.
- Trial name
- BITE (NCT03010436)
- Testing
- Benralizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Jewish Health